The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies

P Moreau - Seminars in hematology, 2012 - Elsevier
Treatment of relapsed or refractory multiple myeloma (MM) continues to present a
therapeutic challenge. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide …
被引用次数：68 相关文章

[引用][C] The future of therapy for relapsed/refractory multiple myeloma emerging agents and novel treatment strategies

P MOREAU - Semin Hematol, 2012 - cir.nii.ac.jp

[引用][C] The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

P MOREAU - Seminars in hematology, 2012 - pascal-francis.inist.fr
The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and
Novel Treatment Strategies CNRS Inist Pascal-Francis CNRS Pascal and Francis …

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

P Moreau - Seminars in Hematology, 2012 - europepmc.org
Treatment of relapsed or refractory multiple myeloma (MM) continues to present a
therapeutic challenge. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide …

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies

P Moreau - Seminars in hematology, 2012 - pubmed.ncbi.nlm.nih.gov
Treatment of relapsed or refractory multiple myeloma (MM) continues to present a
therapeutic challenge. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide …

[引用][C] The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

P MOREAU - Seminars in hematology, 2012 - Elsevier